Intervest begins development works at Herentals Inexperienced Logistics


Globe Newswire

Autolus Therapeutics announces the appointment of Martin Murphy as non-executive chairman

LONDON, May 23 / PRNewswire / – Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies, announced today that Dr. Martin Murphy has been appointed non-executive chairman of Dr. Christian Itin has been Chairman of the Autolus Board of Directors since it was founded in 2014 and has also been Chief Executive Officer since 2016. As the company’s lead program (AUTO1) continues to advance in multiple clinical trials and the company is beginning to prepare for commercialization in the event AUTO1 receives regulatory approval. The company believes that the complexity of the business warrants a separation of the roles of chairman and chief executive officer so that Dr. Itin can fully concentrate on running the business enterprise. He remains a member of the Autolus board of directors. Dr. Murphy has over 25 years of life science experience and joined the Autolus board as a non-executive director when the company was founded in 2014. He is currently the Chief Executive Officer of Syncona Investment Management Limited, an FTSE-250 listed healthcare investment company and a founding investor of Autolus. He has or previously served in the role of non-executive chairman on the boards of several life science companies. About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next generation programmed T-cell therapies for the treatment of cancer. The company uses a wide range of proprietary and modular T-cell programming technologies to develop precisely targeted, controlled, and highly active T-cell therapies that can better identify cancer cells, destroy their defense mechanisms and eliminate these cells. Autolus has a number of product candidates for the treatment of hematological malignancies and solid tumors. More information is available at About AUTO1 AUTO1 is a CD19-CAR T-cell exploratory therapy designed to overcome the limitations of clinical activity and safety compared to current CD19-CAR T-cell therapies. AUTO1 is designed to have a rapid target binding off rate to minimize overactivation of programmed T cells. It can decrease toxicity and be less prone to T cell depletion, which could improve persistence and improve the ability of programmed T cells to participate in series killing of target cancer cells. In collaboration with our academic partner UCL, AUTO1 is currently being evaluated in a phase 1 clinical trial in ALL and B-NHL for adults. The company has also advanced AUTO1 into a Phase 1/2 clinical trial, known as the FELIX trial, which is a potential key trial. About the AUTO1-FELIX study The Phase 1/2 clinical study (FELIX) is currently enrolling adult patients with relapsed / refractory ALL. The trial has a limited phase 1b component before entering into a single arm phase 2 clinical trial. The primary endpoint is overall response rate and key secondary endpoints include duration of response, MRD negative CR rate, and safety. The study is expected to enroll approximately 100 patients in 30 of the leading academic and non-academic centers in the US, UK and Europe. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and, in some cases, can be identified by words such as “may”, “will” “,” could “,” expects “,” plans “,” anticipates “and” believes “. These statements include, but are not limited to, statements about the development of the AUTO1 program, including progress, patient recruitment, expectations regarding reporting of data, behavior and timing, and potential future clinical activities and regulatory approval, behavior and timing. All forward-looking statements are based on management’s current beliefs and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. These risks and uncertainties include, but are not limited to, the risks that Autolus’ preclinical or clinical programs will not result in timely or inexpensive or not approved or approved products at all. The results of early clinical studies do not always suggest future results. Costs, timing and results of clinical studies; that many product candidates do not become approved drugs on time, or at low cost, or not at all; the ability to enroll patients in clinical trials; possible safety and effectiveness concerns; and the impact of the ongoing COVID-19 pandemic on Autolus’ business. For more information about other risks and uncertainties, as well as other important factors that could cause Autolus’ actual results to differ from those contained in the forward-looking statements, please refer to the “Risk Factors” section of the Autolus Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 4, 2021, as amended, and discussion of potential risks, uncertainties and other important factors in Autolus’ subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of publication and Autolus assumes no obligation to publicly update any forward-looking statements as a result of new information, future events or otherwise, except as required by law. Contact: Julia Wilson + 44 (0) 7818 Susan A. NoonanS.A. Noonan Communications